Insulet's Q2 revenue of $488M exceeded estimates, driven by strong Omnipod 5 demand and international growth. Insulet raised its full-year revenue forecast to 18%-21% growth, up from the previous ...
InsuletPODD stock hit a new high of 337.26 on Thursday. Shares are in a buy zone. The IBD Sector Leader makes the Omnipod insulin pump for people with diabetes. Insulet is expanding the use of its ...
Insulet PODD posted solid second-quarter results that were largely consistent with our expectations, and our small adjustments to our underlying assumptions weren’t enough to move the needle on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback